Last reviewed · How we verify

KPI-121 0.25% Ophthalmic Suspension

Kala Pharmaceuticals, Inc. · Phase 3 active Small molecule

KPI-121 0.25% Ophthalmic Suspension is a Ophthalmic anti-inflammatory suspension Small molecule drug developed by Kala Pharmaceuticals, Inc.. It is currently in Phase 3 development for Dry eye disease (keratoconjunctivitis sicca), Post-operative ocular inflammation. Also known as: Loteprednol etabonate, Loteprednol etabonate 0.25%.

KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact.

KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact. Used for Dry eye disease (keratoconjunctivitis sicca), Post-operative ocular inflammation.

At a glance

Generic nameKPI-121 0.25% Ophthalmic Suspension
Also known asLoteprednol etabonate, Loteprednol etabonate 0.25%
SponsorKala Pharmaceuticals, Inc.
Drug classOphthalmic anti-inflammatory suspension
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

KPI-121 is a novel ophthalmic suspension containing a proprietary mucoadhesive polymer system that enhances corneal and conjunctival residence time. The formulation is designed to reduce inflammation and provide lubrication to the ocular surface, addressing both the inflammatory and aqueous-deficient components of dry eye disease. The mucoadhesive properties allow for prolonged therapeutic contact with the eye surface, potentially improving efficacy compared to standard eye drops.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about KPI-121 0.25% Ophthalmic Suspension

What is KPI-121 0.25% Ophthalmic Suspension?

KPI-121 0.25% Ophthalmic Suspension is a Ophthalmic anti-inflammatory suspension drug developed by Kala Pharmaceuticals, Inc., indicated for Dry eye disease (keratoconjunctivitis sicca), Post-operative ocular inflammation.

How does KPI-121 0.25% Ophthalmic Suspension work?

KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact.

What is KPI-121 0.25% Ophthalmic Suspension used for?

KPI-121 0.25% Ophthalmic Suspension is indicated for Dry eye disease (keratoconjunctivitis sicca), Post-operative ocular inflammation.

Who makes KPI-121 0.25% Ophthalmic Suspension?

KPI-121 0.25% Ophthalmic Suspension is developed by Kala Pharmaceuticals, Inc. (see full Kala Pharmaceuticals, Inc. pipeline at /company/kala-pharmaceuticals-inc).

Is KPI-121 0.25% Ophthalmic Suspension also known as anything else?

KPI-121 0.25% Ophthalmic Suspension is also known as Loteprednol etabonate, Loteprednol etabonate 0.25%.

What drug class is KPI-121 0.25% Ophthalmic Suspension in?

KPI-121 0.25% Ophthalmic Suspension belongs to the Ophthalmic anti-inflammatory suspension class. See all Ophthalmic anti-inflammatory suspension drugs at /class/ophthalmic-anti-inflammatory-suspension.

What development phase is KPI-121 0.25% Ophthalmic Suspension in?

KPI-121 0.25% Ophthalmic Suspension is in Phase 3.

What are the side effects of KPI-121 0.25% Ophthalmic Suspension?

Common side effects of KPI-121 0.25% Ophthalmic Suspension include Blurred vision, Eye irritation, Conjunctival hyperemia, Ocular discomfort.

Related